Yigang Jin

Jul 16, 2024 | molecular-cancer.biomedcentral.com | Zhaoyang Zhu |Yigang Jin |Jing Zhou |fei chen |Minjie Chen |Zhaofeng Gao | +5 more

Currently, PD1/PD-L1 inhibitors have become an important class of immunotherapy in the treatment of ccRCC. Their clinical efficacy has been validated in multiple clinical trials. In this section, we will summarize the main clinical trial data of PD1/PD-L1 inhibitors in the treatment of ccRCC, including the trial results of drugs such as Nivolumab and Pembrolizumab. We will explore the efficacy of PD1/PD-L1 inhibitors, common resistance mechanisms, and strategies to address resistance.

Jul 5, 2024 | aging-us.com | Yigang Jin |Minjie Chen |fei chen |Zhaofeng Gao

Research Paper Volume 16, Issue 13 pp 11072—11089 1 Department of Urology, The Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, China 2 Department of Surgery, The Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, China * Co-first authorship https://doi.org/10.18632/aging.206006 How to Cite Cite this Article Select the format you require from the list below Click to copy this citation from the text box above or download the citation: Citation | Copyright:...